This inventor holds 10 USPTO granted patents and 1 published patent application, plus 1 CIPO patent. Top assignees: Health Research, Inc., Virginia Commonwealth University. Active years: 2006-2019.
Location History:
- Williamsville, NY (US) (2006 - 2012)
- Buffalo, NY (US) (2017 - 2019)
Company Filing History:

Years Active: 2006-2019
Title: The Innovative Contributions of John R. Subjeck
Introduction
John R. Subjeck is a prominent inventor based in Buffalo, NY (US), known for his significant contributions to the field of immunotherapy and vaccine formulation. With a total of 10 patents to his name, Subjeck has made remarkable strides in developing innovative solutions for the treatment and prevention of cancer and infectious diseases.
Latest Patents
Among his latest patents is the development of an immune modulator for immunotherapy and vaccine formulation. This invention features a recombinant Flagrp170 protein and pharmaceutical compositions that include this protein and related molecules. The Flagrp170 protein is designed with an NF-κB-activating domain of Flagellin and an ATP-binding domain truncated Grp170. The pharmaceutical compositions derived from this invention hold promise for treating or preventing various cancers and infectious diseases.
Career Highlights
Throughout his career, John R. Subjeck has worked with notable organizations such as Health Research, Inc. and Virginia Commonwealth University. His work in these institutions has allowed him to advance his research and contribute to the scientific community significantly.
Collaborations
Subjeck has collaborated with esteemed colleagues, including Xiang-Yang Wang and Robert A. Henderson. These partnerships have further enriched his research endeavors and have led to the development of impactful innovations.
Conclusion
John R. Subjeck's innovative work in immunotherapy and vaccine formulation exemplifies the vital role of inventors in advancing medical science. His contributions continue to pave the way for new treatments that can improve patient outcomes.